ReviewFrontiers in cell and developmental biology2026
Cardiac EndMT and EpiMT as a developmental continuum: integration of mechanical, metabolic, and epigenetic regulation.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac epithelial-mesenchymal transition (EMT) is a conserved morphogenetic program that shapes embryonic heart development and contributes to disease when aberrantly reactivated. Two major forms of cardiac EMT, endocardial-to-mesenchymal transition (EndMT) and epicardial epithelial-to-mesenchymal transition (EpiMT), support valve and septal formation, outflow tract remodeling, coronary vascular maturation, myocardial growth, and cardiac fibroblast generation. Increasing evidence indicates that these processes are not binary cell fate switches, but dynamic and context-dependent continua governed by coordinated signaling, mechanical, metabolic, extracellular matrix, and epigenetic inputs. In this review, we synthesize classical and emerging mechanisms regulating EndMT and EpiMT, including TGF-β/BMP, Notch, ErbB, Wnt/β-catenin, FGF, YAP/TAZ, chromatin remodeling, and non-coding RNA networks. We propose that developmental EndMT is best understood as a regionally licensed continuum of endocardial cell states in the atrioventricular canal and outflow tract, whereas developmental EpiMT represents a niche-dependent lineage continuum shaped by epicardial competence, myocardial-derived cues, mechanical environment, and post-EMT lineage allocation. This framework helps explain why similar regulatory pathways can generate distinct morphogenetic, fibrotic, or reparative outcomes depending on developmental stage, anatomical context, and cellular state. We further discuss how aberrant EndMT and EpiMT contribute to congenital heart disease, including valve malformations, septal defects, outflow tract defects, coronary abnormalities, and ventricular hypoplasia. Finally, we evaluate emerging approaches, including single-cell multi-omics, spatial transcriptomics, lineage tracing, live imaging, patient-specific induced pluripotent stem cell models, organoids, and human-based new alternative methodologies, as tools for resolving EMT heterogeneity, testing causal mechanisms, and defining therapeutic safety boundaries. Understanding cardiac EndMT and EpiMT as evidence-aware, context-dependent developmental continua may refine the interpretation of congenital and adult cardiac disease and inform future studies evaluating whether pathological EMT-related plasticity can be selectively modulated without impairing repair or vascular homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.